Pulmonx Corp
LUNG
查看详细走势图
2.600USD
+0.080+3.17%
收盘 12/19, 16:00（美东）报价延迟15分钟
107.24M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.17%
5天
+2.77%
1月
+80.56%
6月
-0.76%
今年开始到现在
-61.71%
1年
-57.72%
查看详细走势图
TradingKey Pulmonx Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
Pulmonx Corp当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名70/208位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.75。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Pulmonx Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
5.750
目标均价
+181.86%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Pulmonx Corp亮点
亮点风险
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
业绩高增长
公司营业收入稳步增长，连续3年增长56.14%
业绩增长期
公司处于发展阶段，最新年度总收入83.79M美元
估值高估
公司最新PE估值-1.84，处于3年历史高位
机构减仓
最新机构持股35.49M股，环比减少17.02%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值4.19K
活跃度增加
近期活跃度增加，过去20天平均换手率1.32
Pulmonx Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Pulmonx Corp简介
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
公司代码LUNG
公司Pulmonx Corp
CEOFrench (Glendon E)
网址https://pulmonx.com/
常见问题
Pulmonx Corp(LUNG)的当前股价是多少？
Pulmonx Corp(LUNG)的当前股价是 2.600。
Pulmonx Corp的股票代码是什么？
Pulmonx Corp的股票代码是LUNG。
Pulmonx Corp股票的52周最高点是多少？
Pulmonx Corp股票的52周最高点是9.370。
Pulmonx Corp股票的52周最低点是多少？
Pulmonx Corp股票的52周最低点是1.310。
Pulmonx Corp的市值是多少？
Pulmonx Corp的市值是107.24M。
Pulmonx Corp的净利润是多少？
Pulmonx Corp的净利润为-56.39M。
现在Pulmonx Corp(LUNG)的股票是买入、持有还是卖出？
根据分析师评级，Pulmonx Corp(LUNG)的总体评级为买入，目标价格为5.750。
Pulmonx Corp(LUNG)股票的每股收益（EPS TTM）是多少
Pulmonx Corp(LUNG)股票的每股收益（EPS TTM）是-1.410。
相关品种
-0.24%
+0.25%
+0.87%
+1.88%
+0.22%
-0.55%
+0.53%
+0.12%
+1.35%
-0.10%
-1.23%
-0.77%
+0.10%
+0.46%
+0.46%
+0.97%
+0.59%
+0.23%
+0.45%
+1.74%
